TVGN Valuation

Tevogen Bio Holdings Inc

Add to Watchlist

Advanced Chart

0.963

-0.017(-1.735%)1D

Overview
Forecast
Valuation
Earnings

TVGN Relative Valuation

TVGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TVGN is overvalued; if below, it's undervalued.

Get winning stock picks in minutes

Historical Valuation

Tevogen Bio Holdings Inc (TVGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.63. The fair price of Tevogen Bio Holdings Inc (TVGN) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.96

Fair

-4.22

Trailing

Forward

0.00

EV/EBITDA

Tevogen Bio Holdings Inc. (TVGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-4.49

EV/EBIT

Tevogen Bio Holdings Inc. (TVGN) has a current EV/EBIT of -4.49. The 5-year average EV/EBIT is -0.64. The thresholds are as follows: Strongly Undervalued below -4.00, Undervalued between -4.00 and -2.32, Fairly Valued between 1.03 and -2.32, Overvalued between 1.03 and 2.71, and Strongly Overvalued above 2.71. The current Forward EV/EBIT of -4.49 falls within the Strongly Undervalued range.

0.00

Tevogen Bio Holdings Inc. (TVGN) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-4.23

P/OCF

Tevogen Bio Holdings Inc. (TVGN) has a current P/OCF of -4.23. The 5-year average P/OCF is -0.61. The thresholds are as follows: Strongly Undervalued below -3.80, Undervalued between -3.80 and -2.20, Fairly Valued between 0.98 and -2.20, Overvalued between 0.98 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/OCF of -4.23 falls within the Strongly Undervalued range.

-4.23

P/FCF

Tevogen Bio Holdings Inc. (TVGN) has a current P/FCF of -4.23. The 5-year average P/FCF is -0.61. The thresholds are as follows: Strongly Undervalued below -3.80, Undervalued between -3.80 and -2.20, Fairly Valued between 0.98 and -2.20, Overvalued between 0.98 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/FCF of -4.23 falls within the Strongly Undervalued range.

Tevogen Bio Holdings Inc (TVGN) has a current Price-to-Book (P/B) ratio of -10.91. Compared to its 3-year average P/B ratio of -11.82 , the current P/B ratio is approximately -7.74% higher. Relative to its 5-year average P/B ratio of -12.33, the current P/B ratio is about -11.55% higher. Tevogen Bio Holdings Inc (TVGN) has a Forward Free Cash Flow (FCF) yield of approximately -6.92%. Compared to its 3-year average FCF yield of -5.81%, the current FCF yield is approximately 19.13% lower. Relative to its 5-year average FCF yield of -5.81% , the current FCF yield is about 19.13% lower.

-10.91

P/B

Median3y

-11.82

Median5y

-12.33

-6.92

FCF Yield

Median3y

-5.81

Median5y

-5.81

Get winning stock picks in minutes

Competitors Valuation Multiple

The average P/S ratio for TVGN's competitors is 9.13, providing a benchmark for relative valuation. Tevogen Bio Holdings Inc Corp (TVGN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TVGN.O

Tevogen Bio Holdings Inc

Contineum Therapeutics Inc

30.05

189.28M

LYEL.O

Lyell Immunopharma Inc

Greenwich Lifesciences Inc

Loss

165.10M

CRBU.O

Caribou Biosciences Inc

Voyager Therapeutics Inc

4.70

-82.42%

188.04M

Performance Decomposition

Market capitalization of TVGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of TVGN in the past 1 year is driven by Unknown.